Gaucher Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Gaucher disease (GD) is a lysosomal storage disorder characterized by three primary forms (types 1, 2, and 3), a fetal variant, and a variant involving cardiac issues, known as Gaucher disease with ophthalmoplegia and cardiovascular calcification, or Gaucher-like disease. The root cause of GD lies in mutations within the GBA gene located on chromosome 1q21. This gene is responsible for encoding a crucial lysosomal enzyme called glucocerebrosidase. In exceptionally rare instances, mutations in the PSAP gene, responsible for producing the activator protein saposin C for glucocerebrosidase, can also lead to GD. The insufficiency of glucocerebrosidase leads to the buildup of deposits primarily composed of glucosylceramide (or beta-glucocerebrosidase) within the cells of the reticuloendothelial system, with the most significant impact observed in the liver, spleen, and bone marrow. These cells are referred to as Gaucher cells. The formal diagnosis of GD relies on measuring the levels of glucocerebrosidase in circulating leukocytes, with genotyping being employed to confirm the diagnosis. When making a differential diagnosis, it is important to consider other lysosomal storage disorders. Gaucher-like cells may also be present in certain hematologic conditions, such as lymphoma, Hodgkin's lymphoma, and chronic lymphocytic leukemia. Prognosis varies depending on the GD type. GD type 1 generally has a favorable prognosis, whereas GD type 2 typically leads to death before age 2. Without specific treatment, GD type 3 progresses, ultimately resulting in death within a few years.

·       The global prevalence estimates for any GD per 100,000 population range widely from 0.02 to 139.0.

 

Thelansis’s “Gaucher Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Gaucher Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Gaucher Disease across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Gaucher Disease Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Gaucher Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Gaucher Disease, Gaucher Disease market outlook, Gaucher Disease competitive landscape, Gaucher Disease market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)